Dendritic Cells and Their Role in Immunotherapy
نویسندگان
چکیده
منابع مشابه
Dendritic Cells and Their Role in Cancer Immunotherapy
Dendritic cells (DCs) are antigen presenting cells with unique capability to take up and process antigens in the peripheral blood and tissues. They subsequently migrate to draining lymph nodes where they present these antigens and stimulate naive T lympho-cytes. During their life cycle, DCs go through two maturation stages and are referred to as immature and mature cells, respectively. While im...
متن کاملdendritic cells and their role in cancer immunotherapy
dendritic cells (dcs) are antigen presenting cells with unique capability to take up and process antigens in the peripheral blood and tissues. they subsequently migrate to draining lymph nodes where they present these antigens and stimulate naive t lympho-cytes. during their life cycle, dcs go through two maturation stages and are referred to as immature and mature cells, respectively. while im...
متن کاملUnderstanding Dendritic Cells and Their Role in Cutaneous Carcinoma and Cancer Immunotherapy
Dendritic cells (DC) represent a diverse group of professional antigen-presenting cells that serve to link the innate and adaptive immune systems. Their capacity to initiate a robust and antigen-specific immune response has made them the ideal candidates for cancer immunotherapies. To date, the clinical impact of DC immunotherapy has been limited, which may, in part, be explained by the complex...
متن کاملDendritic cells in cancer immunotherapy
Dendritic cells (DCs) play a central role in the initiation and regulation of innate and adaptive immune responses and have increasingly been applied as vaccines for cancer patients. Ex vivo generation and antigen loading of monocyte-derived DCs allows a controlled maturation, with the aim of imprinting different DC functions that are essential for their subsequent induction of a T cell-mediate...
متن کاملDendritic Cell Immunotherapy, the Next Step in Cancer Treatment
Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Immunology
سال: 2020
ISSN: 1664-3224
DOI: 10.3389/fimmu.2020.00924